Rand ARAFEH
@randarafeh
Cancer genetics and functional genomics researcher using CRISPR screens to uncover drug-target combination opportunities.
United StatesWhat I'm looking for
I run genome-scale combinatorial CRISPR knockout screens at Dana-Farber Cancer Institute / Broad Institute (Hahn Lab) to map genetic interaction networks in KRAS-mutant cancers and identify candidate combination drug targets.
Before that, I carried out genome-scale double-knockout genetic screens and mechanistic analysis of PP2A regulatory subunit assembly as a tumor suppressor during my postdoctoral work at Dana-Farber / Broad.
At Weizmann Institute of Science, my Ph.D. work led to first-author discovery of RASA2 as a melanoma tumor suppressor through unbiased genomic analysis of 500+ exomes/genomes.
Across roles, I’ve advised on preclinical xenograft study design as a Research Advisor / Consultant at Synergy Med and supported bench experimentation and trainees across 15+ projects.
Experience
Work history, roles, and key accomplishments
Research Scientist I
Dana-Farber Cancer Institute / Broad Institute of MIT and Ha
Feb 2024 - Present (2 years 6 months)
Design and execute genome-scale combinatorial CRISPR knockout screens to map genetic interaction networks in KRAS-mutant cancers and identify candidate combination drug targets.
Scientific Research Mentor
Dana-Farber Cancer Institute / Weizmann Institute of Science
Jan 2011 - Present (15 years 7 months)
Designed and supervised bench experiments across 15+ research projects; mentored rotation students and research assistants.
Postdoctoral Research Fellow
Dana-Farber Cancer Institute / Broad Institute of MIT and Ha
Nov 2018 - Dec 2023 (5 years 1 month)
Executed genome-scale double-knockout genetic screens; conducted genetic, proteomic, and mechanistic analysis of PP2A regulatory subunit assembly as a tumor suppressor.
Research Advisor / Consultant
Synergy Med
Jan 2017 - Dec 2021 (4 years 11 months)
Advised on preclinical xenograft study design (model selection, dosing, delivery route) across breast, melanoma, and head-and-neck cancer.
Ph.D. Researcher — Molecular Cell Biology
Weizmann Institute of Science
Jan 2014 - Dec 2018 (4 years 11 months)
First-author discovery of RASA2 as a novel melanoma tumor suppressor via unbiased genomic analysis of 500+ exomes/genomes. Designed and executed a MEK-inhibitor + ERK nuclear translocation inhibitor combination strategy for NRAS-mutant melanoma.
Education
Degrees, certifications, and relevant coursework
Weizmann Institute of Science
Doctor of Philosophy, Molecular Cell Biology
2014 - 2018
Ph.D. in Molecular Cell Biology, advised by Prof. Yardena Samuels. First-author discovery of RASA2 as a novel melanoma tumor suppressor via unbiased genomic analysis of 500+ exomes/genomes.
Hebrew University of Jerusalem
Master of Science, Immunology, Molecular Cell Biology & Cancer Research
2011 - 2013
M.Sc. in Immunology, Molecular Cell Biology & Cancer Research. Dean's List.
Université Claude Bernard Lyon 1
Bachelor of Science, Genetics and Cell Biology
2007 - 2011
B.Sc. in Biology with honors in Genetics and Cell Biology.
Availability
Location
United StatesAuthorized to work in
Job categories
Skills
Interested in hiring Rand?
You can contact Rand and 90k+ other talented remote workers on Himalayas.
Message RandGet matched with your dream remote job
Sign up now and join over 250,000+ remote workers who receive personalized job alerts, curated job matches, and more for free!
